ENTERA BIO LTD. Deferred Tax Assets, Operating Loss Carryforwards
ENTERA BIO LTD. (ENTX) had Deferred Tax Assets, Operating Loss Carryforwards of $21.11 million as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-27
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $21.11M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $19.21M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $17.43M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $15.43M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $21.11M 10-K · filed 2026-03-27 |
| 2024-12-31 | $19.21M 10-K · filed 2026-03-27 |
| 2023-12-31 | $17.43M 10-K · filed 2025-03-28 |
| 2022-12-31 | $15.43M 10-K · filed 2024-03-08 |
| 2021-12-31 | $12.89M 10-K · filed 2023-03-31 |
| 2020-12-31 | $10.18M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |